Werfen

Werfen is a family-owned diagnostics company headquartered in Barcelona, Spain. Its origins date to 1966, when José María Rubiralta founded Izasa as a privately owned distributor of clinical diagnostic products. The company describes itself today as a worldwide leader in specialized diagnostics, with expertise spanning Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant. Its offerings serve clinical laboratories and hospital teams. In Hemostasis, Werfen provides in vitro diagnostic systems, reagents, data-management solutions, automation, and services used to diagnose and guide treatment of thrombotic and bleeding disorders. Its Acute Care Diagnostics portfolio focuses on integrated whole-blood testing for settings such as cardiovascular operating rooms, catheterization laboratories, intensive care units, and emergency departments. The Transfusion portfolio includes serology reagents, automated instrumentation, data-management software, and molecular products. The company’s website also identifies transplant diagnostics as an area of activity, including through its 2024 acquisition of Omixon, a developer and commercializer of next-generation sequencing technologies for transplant diagnostics. Werfen reports operating directly in 30 countries and serving more than 100 territories through distributors. Its headquarters are in Barcelona, and its Technology Centers are located in the United States and Europe. The company reported a workforce of 7,000 and worldwide sales of almost €2.2 billion in 2024. Its stated purpose is to develop innovations intended to enhance patient care and contribute to healthier societies.

Werfen traces its origins to 1966, when José María Rubiralta founded Izasa in Barcelona as a privately owned distributor of clinical diagnostic products. The company’s official history identifies this as the foundation of what later became Werfen. Its early development included moves from distribution into manufacturing and scientific instrumentation: Biokit was founded in Barcelona in 1973, and Instrumentación Científica was founded there in 1974. The history also records geographical expansion into Latin America in 1979 and the founding of Leventon, marking an entry into medical-device manufacturing. A major step in building Werfen’s specialized diagnostics business came in 1991 with the acquisition of Instrumentation Laboratory, identified by the company as a global leader in Hemostasis and Acute Care Diagnostics systems. In 1996, Werfen acquired Chromogenix in Sweden and Mallinckrodt Sensor Systems in the United States, expanding its Hemostasis and Acute Care activities. The 1999 acquisition of Hemoliance further strengthened its position in Hemostasis. The company broadened its diagnostic areas through acquisitions in the following decade. In 2008, it acquired Inova Diagnostics, which its history describes as a leader in Autoimmunity Diagnostics. In 2009, it acquired the autoimmune diagnostics business of The Binding Site Ltd. The company inaugurated Torre Werfen as its new Barcelona headquarters in 2011. Its official history page also lists a 2012 generational change, although the supplied page excerpt does not provide further details. Werfen describes itself as a growing, family-owned company and a worldwide leader in specialized diagnostics. It reports direct operations in 30 countries and distributor coverage in more than 100 territories, with headquarters in Barcelona and Technology Centers in the United States and Europe. Its current areas of expertise include Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant. In October 2024, Werfen completed the acquisition of Omixon, a privately held Budapest-based company focused on next-generation sequencing technologies in transplant diagnostics. Werfen reported almost €2.2 billion in worldwide sales and a workforce of 7,000 in 2024.

• 2024

  Omixon acquisition completed

• 2012

  Generational change

• 2011

  Torre Werfen inaugurated

• 2009

  The Binding Site autoimmune diagnostics business acquired

• 2008

  Inova Diagnostics acquired

• 1999

  Hemoliance acquired

• 1996

  Chromogenix and Mallinckrodt Sensor Systems acquired

• 1991

  Instrumentation Laboratory acquired

• 1979

  Expansion into Latin America and founding of Leventon

• 1974

  Instrumentación Científica founded

• 1973

  Biokit founded

• 1966

  Izasa founded in Barcelona

A family-owned global specialist in diagnostics, focused on clinical areas including hemostasis, acute care, transfusion, autoimmunity, and transplantation, with an emphasis on patient care and laboratory and hospital workflows.

• Hemostasis

  In vitro diagnostic systems, reagents, data-management solutions, automation, and services for diagnosing and guiding treatment of thrombotic and bleeding disorders.

• Acute Care Diagnostics

  Integrated whole-blood testing solutions for hospital acute-care settings, including operating rooms, catheterization laboratories, intensive care units, and emergency departments.

• Transfusion

  A portfolio that includes serology reagents, automated instrumentation, data-management software, and molecular products.

• Transplant diagnostics

  An area of Werfen’s specialized diagnostics activity that includes Omixon’s next-generation sequencing technologies.

1. 1Home | Werfenwerfen.com
2. 2History | Werfenwerfen.com
3. 3About Werfen | Werfenwerfen.com
4. 4Werfenwikidata.org